[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531084":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":42,"responsibleParty":65,"collaborators":21,"id":68,"slug":21,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":21,"studyType":81,"phases":82,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":45,"whyStopped":21,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Sichuan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sunvozertinib combined with chemotherapy (Pemetrexed +platinum)","EXPERIMENTAL","Sunvozertinib 200mg Quaquedie (QD) combined with chemotherapy (Pemetrexed +platinum)",[13,14],"Drug: Sunvozertinib","Drug: Chemotherapy",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Sunvozertinib","Sunvozertinib 200mg Quaquedie (QD)",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Chemotherapy","Pemetrexed +platinum",[9],[27],{"name":28,"affiliation":29,"role":30},"You Lu, MD","West China Hospital","PRINCIPAL_INVESTIGATOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Li Li, BA","CONTACT","113880343287","+86","tracy.li_2010@hotmail.com",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Feifei Na, MD","18583988151","nafeifei@foxmail.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"West China Hospital of Sichuan University","RECRUITING","Chengdu","Sichuan","610044","China","CN",{"type":52,"coordinates":53},"Point",[54,55],104.06667,30.66667,{"lat":55,"lon":54},[58,61,62,63],{"name":28,"role":34,"phone":59,"phoneExt":21,"email":60},"+8602885423571","radyoulu@hotmali.com",{"name":39,"role":34,"phone":40,"phoneExt":21,"email":41},{"name":28,"role":30,"phone":21,"phoneExt":21,"email":21},{"name":39,"role":64,"phone":21,"phoneExt":21,"email":21},"SUB_INVESTIGATOR",{"type":30,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"You Lu","Chair of Department of Thoracic Oncology","100531084",false,"NCT06195189","Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I\u002FII","Sunvozertinib Combined With Chemotherapy for EGFRm + Locally Advanced or Metastasis NSCLC Patients After EGFR-TKI Treatment Failure：Phase I\u002FII (WU-KONG36)","WU-KONG36","Inclusion Criteria:\n\n1. To provide a signed and dated, written informed consent.\n2. 80≥Age ≥ 18 years old\n3. Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory\n4. EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.\n5. Predicted life expectancy ≥ 12 weeks\n6. EGFR-TKI resistance or intolerant to standard EGFR TKIs therapy.\n7. No previous systemic chemotherapy for advanced or metastatic disease.\n8. Adequate organ system function:\n9. Patient must have measurable disease according to RECIST 1.1.\n10. Patients with stable or pre-treated brain metastasis (BM) can be enrolled\n\nExclusion Criteria:\n\n1. Spinal cord compression or meningeal metastasis\n2. A history of malignant tumors within 2 years.\n3. With known resistant mutations that have approved target therapy\n4. Recover from AEs caused by previous treatment\n5. A history of stroke or intracranial hemorrhage within 6 months prior to initial dosing.\n6. Any severe or poorly controlled systemic disease per investigator's judgment active infections, including but not limited to hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency (HIV)","ALL","18 Years","80 Years",{"count":79,"type":80},40,"ESTIMATED","INTERVENTIONAL",[83,84],"PHASE1","PHASE2","To access the anti-tumor efficacy, safety and tolerability of Sunvozertinib combined with chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations who have progressed following standard TKI therapy.",[87],"Non Small Cell Lung Cancer",[87,18,89,90],"EGFR","chemotherapy","2026-05-04",{"date":93,"type":94},"2026-05-08","ACTUAL",{"date":96,"type":94},"2024-02-29",{"date":98,"type":80},"2028-12-30",{"name":5,"class":6},1]